Difference between revisions of "Eptifibatide (Integrilin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Integrilin | *'''Brand name:''' Integrilin | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:GPIIb-IIIa inhibitors]] | [[Category:GPIIb-IIIa inhibitors]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1998]] |
Latest revision as of 00:58, 29 June 2024
General information
Class/mechanism: reversibly inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Also known as
- Brand name: Integrilin